

- a) contacting the sample with a human neuronal ICAM-4 specific antibody, and
- b) detecting an antigen comprising an epitope specifically recognized by an anti-human neuronal ICAM-4 antibody.

<sup>19</sup>  
~~34~~. The method of claim <sup>18</sup>~~33~~ wherein the antibody is a monoclonal antibody.

<sup>20</sup>  
~~35~~. The method according to claim <sup>18</sup>~~33~~ wherein the anti-ICAM-4 monoclonal antibody is selected from the group consisting of the monoclonal antibody secreted by hybridoma 173E, the monoclonal antibody secreted by hybridoma 179I and the monoclonal antibody secreted by hybridoma 179H.

<sup>21</sup>  
~~36~~. The method of any one of claims <sup>18-20</sup>~~33-35~~ wherein the sample comprises a body fluid.

<sup>22</sup>  
~~37~~. The method of claim <sup>21</sup>~~36~~ wherein the body fluid is selected from the group consisting of serum and cerebrospinal fluid.

<sup>23</sup>  
~~38~~. Hybridoma 179I (American Type Culture Collection Accession No. HB12123)

<sup>24</sup>  
~~39~~. The monoclonal antibody secreted by hybridoma 179I.

<sup>25</sup>  
~~40~~. Hybridoma 179H (American Type Culture Collection Accession No. HB12124)

<sup>26</sup>  
~~41~~. The monoclonal antibody secreted by hybridoma 179H.